诺华启动高达100亿美元回购，提升前景

• Novartis (NYSE:NVS) announced the launch of a new share buyback program of up to $10 billion, reflecting increased confidence in its financial strength and growth prospects.
• The buyback is scheduled to be completed by the end of 2027
• The announcement came alongside a Q2 bottom-line beat, and the drugmaker confirmed that it now expects core operating income to increase by a low-teens percentage, compared with the low double-digits cited previously.
• "Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation," said Chief Executive Vas Narasimhan.
• The decision was underpinned by robust financial performance during the recent quarter, including strong growth from key drugs such as Kisqali for breast cancer.

More on Novartis

• Why Novartis Is Still A 'Buy' After 15% Surge
• Novartis: A SWAN Worth Owning
• Novartis: 2025 Guidance Raised To Top End Of Prior Range - Buy Confirmed
• Novartis Non-GAAP EPS of $2.42 beats by $0.05, revenue of $14.05B in-line; updates FY outllook
• Novartis Q2 2025 Earnings Preview